Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...
Pharmaceutical Technology on MSN13d
Callio raises $187m for proof-of-concept for dual-payload ADC
Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human ...
Newly launched Seattle cancer therapy startup Callio Therapeutics raises $187M
Biotech-focused investment firm Frazier Life Sciences launched Callio Therapeutics, a cancer treatment startup with headquarters in Seattle and Singapore.
Longview News-Journal15d
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Pureos Bioventures, SEEDS Capital and EDBI Company to advance innovative multi-payload programs designed to maximize therapeutic benefit for cancer patients by overcoming limitations of existing ...